期刊文献+

减低剂量地西他滨治疗中高危骨髓增生异常综合征的效果分析 被引量:2

下载PDF
导出
摘要 目的对比性分析减低剂量地西他滨治疗中高危骨髓增生异常综合征(MDS)的疗效及安全性。方法选取2012年8月至2015年8月于郑州大学第一附属医院就诊的MDS患者61例,根据治疗方案不同分为观察组29例和对照组32例,观察组采用减低剂量地西他滨治疗,对照组采用预激方案治疗,观察两组患者的治疗效果和不良反应发生情况。结果两组治疗总有效率差异无统计学意义(P>0.05)。观察组感染、恶心呕吐、心功能异常和肝肾功异常发生率明显低于对照组,差异有统计学意义(P<0.05)。结论减低剂量地西他滨可有效治疗中高危MDS,不良反应发生率低于预激方案,患者耐受性良好。
出处 《河南医学研究》 CAS 2016年第4期667-668,共2页 Henan Medical Research
  • 相关文献

参考文献5

  • 1Blum W.How Much?How Frequent?How Long?A clinical Guide to New Therapies in Myelodysplastic syndroms[J].Hemology Am Soc Hematol Educ Program,2010,2010:314-321.
  • 2Lubbert M,Suciu S,Baila L,et al.Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk myelodysplastic syndrome ineligible for intenstive chemoterapy:final results of the randomized phaseⅢstudy of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS study Group[J].J Clin Oncol,2011,29(15):1987-1996.
  • 3谢伟成,程淑琴,林翠芳,谢碧霞.地西他滨治疗骨髓增生异常综合征的临床疗效研究[J].临床和实验医学杂志,2014,13(11):877-880. 被引量:21
  • 4王浩,谢佳,刘秋艳,刘锋,宋艳萍.探索不同剂量地西他滨对骨髓增生异常综合征的临床效果[J].中国医学前沿杂志(电子版),2015,7(7):88-91. 被引量:4
  • 5Santos F P,Kantarjian H,Garcia-Manero G,et al.Decitabine in the treatment of myelodysplastic syndromes[J].Expert Rev Anticancer Ther,2010,10(1):9-22.

二级参考文献27

  • 1王战营,郭宏岗,张莳,等.HAG方案治疗老年急性髓系白血病16例疗效分析[J].中国医师进修杂志,2012,9(35):57-58.
  • 2Bennett JM, MDS Foundationg Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syn- dromes[ J]. Am J Hematol, 2008,83 ( 11 ) :858 - 861.
  • 3Nimer SD. Myelodysplastic syndromes [ J]. Blood, 2008,111 (10) : 4841 - 4851.
  • 4Park M J, Kim H J, Kim SH, et al. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients withmyelodysplastic syndrome? External validation of the WHO Classification - Based Prognostic Scoring System (WIS) and comparison with IPSS [J]. Eur J Haematol, 2008,81 (5) :364-373.
  • 5Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensusstatements and report from a working conference [ J ]. Leuk Res, 2007,31 (6) :727 - 736.
  • 6Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J]. Blood, 2006,108(2) :419 -425.
  • 7Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2. 0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy[ J]. Int J Radiat Oncol Biol Phys, 2000, 47(1) :13 -47.
  • 8Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myeIodysplastic syndrome previously treated with azacitidine [J]. Leuk Lymphoma, 2008,49(4) :690 -695.
  • 9Moreno - Aspitia A, Colon - Otero G, Hoering A, et al. Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial [ J ]. Cancer, 2006, 107 (4) :767 -772.
  • 10Greenberg P,Cox C,Le Beau MM,et al.International scoring system for evaluating prognosis in myelodysplastic syndromes[J].Blood,1997,89(6):2079-2088.

共引文献23

同被引文献22

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部